Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.54 USD
Change Today +0.02 / 3.85%
Volume 264.1K
CVM On Other Exchanges
Symbol
Exchange
Stuttgart
NYSE Amex
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cel-sci corp (CVM) Snapshot

Open
$0.55
Previous Close
$0.52
Day High
$0.56
Day Low
$0.52
52 Week High
03/4/15 - $1.23
52 Week Low
08/26/15 - $0.48
Market Cap
60.5M
Average Volume 10 Days
367.1K
EPS TTM
$-0.37
Shares Outstanding
112.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEL-SCI CORP (CVM)

Related News

No related news articles were found.

cel-sci corp (CVM) Related Businessweek News

No Related Businessweek News Found

cel-sci corp (CVM) Details

CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process, stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, provides peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

cel-sci corp (CVM) Top Compensated Officers

Chief Executive Officer, Treasurer and Direct...
Total Annual Compensation: $584.6K
Founder, Chairman and President
Total Annual Compensation: $393.3K
Senior Vice President of Operations and Corpo...
Total Annual Compensation: $247.9K
Senior Vice President of Research - Cellular ...
Total Annual Compensation: $213.2K
Senior Vice President of Regulatory Affairs
Total Annual Compensation: $197.4K
Compensation as of Fiscal Year 2014.

cel-sci corp (CVM) Key Developments

CEL-SCI Corporation Announces Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015

CEL-SCI Corporation announced earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company has reported net loss of $4.43 million or $0.06 loss per diluted share compared to net loss of $2.44 million or $0.11 loss per diluted share for the same quarter ended June 30, 2014. Grant and other income was $389,223 compared to $15,914 for the same quarter ended June 30, 2014. For the nine months, net loss was $24.83 million or $0.32 loss per share compared to net loss of $20.14 million or $0.38 loss per share for the same period ended June 30, 2014. Grant and other income was $723,681 compared to $196,215 for the same period ended June 30, 2014.

CEL-SCI Corporation Expands Its Phase I Study for Treatment of Anal Warts inHIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco

CEL-SCI Corporation announced it has added a second clinical site for its Phase I clinical trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women with its investigational cancer immunotherapy Multikine (Leukocyte Interleukin, Injection). Dr. Joel Palefsky has joined the study as a Principal Investigator at the University of California San Francisco (UCSF). UCSF becomes the second clinical site for the study. The first site, the U.S. Naval Medical Center San Diego, continues to enroll patients under a Cooperative Research and Development Agreement (CRADA).

CEL-SCI Corporation Presents at AFund Triple Gold Investment Conference, Jul-22-2015 11:20 AM

CEL-SCI Corporation Presents at AFund Triple Gold Investment Conference, Jul-22-2015 11:20 AM. Venue: The Princeton Club, 15 West 43rd Street, 2nd Floor, New York, NY 10036, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CVM:US $0.54 USD +0.02

CVM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CVM.
View Industry Companies
 

Industry Analysis

CVM

Industry Average

Valuation CVM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 57.2x
Price/Book 15.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 60.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEL-SCI CORP, please visit www.cel-sci.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.